Gelonghui, December 29丨Haiwang Biotech (000078.SZ) announced that the company's wholly-owned subsidiary Shenzhen Haiwang Pharmaceutical Technology Research Institute Co., Ltd. (“Haiwang Pharmaceutical Research Institute”) recently received a written notice from the US Food and Drug Administration to approve NEP018, a novel tumor vascular inhibitor independently developed by Haiwang Pharmaceutical Research Institute and with independent intellectual property rights, to carry out human clinical trials of phase I drugs in the US.
NEP018 is a novel tumor vascular inhibitor independently developed by Haiwang Pharmaceutical Research Institute and has independent intellectual property rights. Comprehensive non-clinical studies have shown that NEP018 has an excellent inhibitory effect on highly carcinogenic targets such as VEGFR, c-Met, and NTRK. It has a significant inhibitory effect on gastrointestinal malignancies in animal tumor models, and has an excellent treatment window, showing potential clinical treatment value.
